Skip to main content
. 2016 Sep 13;6:32992. doi: 10.1038/srep32992

Figure 7. Combination of crizotinib and BKM120 synergistically inhibit the growth of patient derived xenografts in nude mice.

Figure 7

Results from PDX experiment testing the efficacy of BKM120 and the combination of crizotinib/BKM120 in inhibiting the growth of tumors in nude mice. Female nude mice of age 5–8 weeks were implanted with low passage CTG-0234 human mesothelioma patient tumor. Oral gavage treatment with combination of crizotinib (25 mg/kg) and BKM120 (10 mg/kg) reduced PDX tumor growth significantly relative to vehicle control. The combined treatment was much more effective than BKM120 alone.